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A STATement on Vemurafenib-
Resistant Melanoma
Edward J. Hartsough1 and Andrew E. Aplin1
Despite recent advancements in the treatment of late-stage mutant BRAF V600E/K
melanomas, a major hurdle continues to be acquired resistance to BRAF inhibitors
such as vemurafenib. The mechanisms for resistance have proven to be
heterogeneous, emphasizing the need to use broad therapeutic approaches. In
this issue, the study ‘‘Stat3-targeted therapies overcome the acquired resistance to
vemurafenib in melanomas’’ by Liu et al. proposes that signal transducer and
activator of transcription 3 (STAT3)–paired box 3 (PAX3) signaling may be a
mechanism that is used by melanomas to resist RAF inhibitors.
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Mutations in the serine/threonine kinase
BRAF are found in 45–50% of melano-
mas. The development of clinical inhi-
bitors to steps in the BRAF/MEK/ERK1/2
pathway has led to US Food and Drug
Administration approval of the RAF
inhibitor vemurafenib in late-stage
mutant BRAF V600E/K melanomas. How-
ever, the initial clinical responses to
vemurafenib are heterogeneous, with
median progression-free survival of only
6 to 7 months. Almost all patients who
experience an initial response ultimately
acquire resistance that allows disease
progression, emphasizing the need to
identify and target mechanisms of resis-
tance to both vemurafenib and other
RAF inhibitors. Several mechanisms
used by the mutant BRAF melanoma
cells to overcome RAF inhibition have
been described previously (Aplin et al.,
2011). Most of these mechanisms, such
as expression of BRAF splice variants,
COT1 expression, and activating MEK1
or NRAS mutations, funnel through the
extracellular signal–regulated kinase 1/2
(ERK1/2) pathway and lead to its reacti-
vation. In this study, Liu et al. (this issue,
2013) implicate an alternative signaling
pathway, signal transducer and activator
of transcription 3 (STAT3)–paired box 3
(PAX3), in RAF inhibitor resistance in
melanoma.
STAT3 is a cytokine-regulated tran-
scription factor activated by JAKs, a
family of nonreceptor tyrosine kinases.
JAKs phosphorylate STAT3 directly,
inducing their dimerization and subse-
quent nuclear translocation. A recent
work from the Cui laboratory has
demonstrated STAT3 as a direct trans-
activator of the PAX3 promoter (Dong
et al., 2012). PAX3, a transcription
factor belonging to the paired class
homeodomain family, has been
implicated in activating expression of
the receptor tyrosine kinase MET in
melanoma (Mascarenhas et al., 2010).
In this study, Liu et al. (this issue, 2013)
show that mutant V600E BRAF enhan-
ces STAT3 phosphorylation and increa-
ses PAX3 expression in melanocytes.
Targeting mutant BRAF signaling with
vemurafenib inhibits STAT3 phosphory-
lation and expression of PAX3; this
effect is attenuated but not eliminated
completely in vemurafenib-resistant
melanoma cells. These data seemingly
oppose previous findings that inhibition
of MEK, the downstream target of
BRAF, leads to increased STAT3 phos-
phorylation (Krasilnikov et al., 2003).
Nevertheless, a striking observation is
that overexpression of a constitutively
active form of STAT3 or wild-type PAX3
renders mutant BRAF melanoma cells
more resistant to vemurafenib in vitro.
An interesting future avenue would be
to address mechanistically how PAX3
contributes to the resistant phenotype. In
addition, these results await support
from vemurafenib-treated patient sam-
ples to determine whether PAX3 expres-
sion correlates with responses. Another
aspect of the study is the extrapolation
from previous studies demonstrating that
secreted basic fibroblast growth factor 2
(bFGF2) derived from keratinocytes acti-
vates STAT3 in melanocytic cells (Dong
et al., 2012). The authors hypothesize
that bFGF2 secreted by melanoma cells
as well as keratinocytes and fibroblasts
in the tumor microenvironment ultima-
tely lead to PAX3 expression. In this
study, Liu et al. (this issue, 2013) were
able to detect elevated levels of secreted
bFGF2 in media of vemurafenib-
resistant cells when compared with
their sensitive parental counterpart. In
addition, the authors demonstrate that
bFGF2 secretion in human primary
fibroblasts and human primary kerati-
nocytes is enhanced in a dose-depen-
dent manner when exposed to
vemurafenib. These data suggest that
bFGF2 secretion is elicited through an
unknown mechanism as a ‘‘protective’’
measure against vemurafenib treatment.
Future studies may be able to link this
vemurafenib-induced bFGF2 secretion
observed from cells present in the
tumor microenvironment to STAT3 sig-
naling and BRAF inhibitor resistance.
Indeed, there is increasing evidence
that stromal-derived factors modulate
responses to RAF inhibitors (Straussman
et al., 2012).
Liu et al. (this issue, 2013) highlight
the importance of the STAT3–PAX3
signaling axis using knockdown experi-
ments and WP1066, a small-molecule
STAT3 inhibitor. Knockdown of either
STAT3 or PAX3 in vemurafenib-resistant
cells reduced growth significantly.
Furthermore, STAT3 knockdown
enhanced the cell’s susceptibility to
vemurafenib substantially, yielding
proof of principal for preclinical
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examination of WP1066. Earlier work
with WP1066 has demonstrated its abil-
ity to block phosphorylation of JAK2 and
STAT3, reduce melanoma proliferation,
and diminish tumor growth in vivo
(Kong et al., 2008). In this study,
WP1066 inhibited phosphorylation of
STAT3 and reduced downstream levels
of PAX3, irrespective of vemurafenib
sensitivity status. In addition, com-
bined treatment with vemurafenib and
WP1066 decreased the number of
vemurafenib-resistant cells more effec-
tively than either drug alone. Although
this work has yet to determine whether
there is mechanistic cooperation bet-
ween V600E BRAF inhibition through
vemurafenib- and WP1066-elicited
reduction in activated STAT3, it sug-
gests that STAT3 targeting in mela-
noma may be effective. Dosing curves
of these drugs in conjunction with either
knockdown or overexpression studies
may provide better insight into poten-
tial synergies. Because STAT3 signaling
seems to be a necessary pathway for
melanoma cell viability, these findings
have translational implications as they
may provide a broad therapeutic
strategy for targeting the heterogeneity
of vemurafenib-resistance mechanisms,
akin to the notion recently proposed for
HSP90 inhibitors (Paraiso et al., 2012).
Although STAT3 inhibitors such as
WP1066 have yet to be evaluated fully
in the clinic, JAK2/STAT3 inhibitors are
currently in phase I/II clinical trials for
head and neck tumors and lymphomas.
This study lays a foundation for addi-
tional preclinical studies on the use of
WP1066 and other STAT3 inhibitors
in patients with vemurafenib-resistant
melanomas.
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Clinical Implications
 Signal transducer and activator of transcription 3 (STAT3) activity and
paired box 3 (PAX3) levels may modulate responses to RAF inhibitors in
mutant BRAF melanomas.
 STAT3 inhibitors are currently being tested in clinical trials.
 Both autocrine and paracrine mechanisms may regulate STAT3–PAX3
signaling in response to RAF inhibitors.
Clinical Implications of CD8þ T-Cell
Infiltration in Frequent and Rare
Cancers
Laurence Feldmeyer1, Olivier Gaide1 and Daniel E. Speiser2
Recent studies of cancer patients revealed high diversity in oncogenic mechan-
isms, leading to increased treatment individualization for subgroups of patients
with frequent cancers. A similar development may not be possible for patients
with rare cancers, such as Merkel cell carcinoma (MCC). Finding shared
disease mechanisms may open new options to understanding and treating such
tumors. Tumor-infiltrating CD8þ T cells are frequently associated with favorable
clinical outcome in a remarkably large spectrum of cancers. In this issue, Afanasiev
et al. suggest a mechanism that may hinder the tumor homing of CD8þ T cells in
MCC patients. It is possible that therapeutic mobilization of anti-cancer T cells
may be useful in patients who share this specific immune biological feature.
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The tumor microenvironment
Cancer cells are surrounded by stromal
cells, blood and lymphatic vessels, and
immune cells. The tumor microenviron-
ment (TME) is not only shaped primarily
by the tumor itself but also strongly
influenced by the host. Our understand-
ing of the role of the immune system
in the TME has increased steadily in
the last decade. Although inflammatory
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